Product Description
Cefetamet is a semisynthetic, beta-lactamase-stable, third-generation cephalosporin with antibacterial activity (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/cefetamet)
Mechanisms of Action: Cell Wall Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Bangladesh | Brazil | China | Colombia | India | Italy | Korea | New Zealand | Peru | Portugal | Sweden | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Korea United Pharm. Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Sinusitis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04664803 |
CASIS | P4 |
Terminated |
Sinusitis |
2019-06-28 |
2020-12-12 |
Primary Endpoints|Treatments |